Citigroup Portfolio holdings
Citigroup Inc., formed in 1998 through the landmark merger of Citicorp and Travelers Group, with roots tracing back to the 1812 founding of City Bank of New York, is a global financial powerhouse headquartered in New York City, managing trillions in assets. Operating in over 160 countries, Citigroup offers a broad spectrum of services, including consumer banking (via Citibank), investment banking, wealth management, and trading, serving millions of retail customers and major corporations, governments, and institutions worldwide. Under CEO Jane Fraser since 2021—the first woman to lead a major U.S. bank—Citigroup has focused on streamlining operations, exiting consumer banking in 13 markets to bolster its institutional and wealth management focus, while navigating post-2008 regulatory scrutiny and fines. Known for its vast global footprint and resilience through crises, Citigroup remains a key player in international finance, blending retail accessibility with high-stakes capital markets expertise.
Top Buys
| 1 |
Invesco QQQ Trust
QQQ
|
+$787M |
| 2 |
CD
Chindata Group Holdings Limited American Depositary Shares
CD
|
+$443M |
| 3 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$401M |
| 4 |
Invesco Dorsey Wright Momentum ETF
PDP
|
+$352M |
| 5 |
Amazon
AMZN
|
+$192M |
Top Sells
| 1 |
Utilities Select Sector SPDR Fund
XLU
|
+$677M |
| 2 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$488M |
| 3 |
Qiagen
QGEN
|
+$484M |
| 4 |
Invesco Dorsey Wright Healthcare Momentum ETF
PTH
|
+$381M |
| 5 |
SPDR S&P 500 ETF Trust
SPY
|
+$379M |
Sector Composition
| 1 | Technology | 17.03% |
| 2 | Consumer Discretionary | 11.26% |
| 3 | Financials | 10.84% |
| 4 | Healthcare | 8.39% |
| 5 | Communication Services | 7.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
551
Integra LifeSciences
IART
$1.17B
| $20.9M | 0.01% |
442,046
-80,329
| -15% | -$3.79M |
|
|
MMP
552
DELISTED
Magellan Midstream Partners, L.P.
MMP
| $20.9M | 0.01% |
610,096
-434,236
| -42% | -$14.9M |
|
553
Republic Services
RSG
$71B
| $20.8M | 0.01% |
222,536
+11,800
| +6% | +$1.1M |
|
554
Ameriprise Financial
AMP
$46.2B
| $20.8M | 0.01% |
134,780
+38,726
| +40% | +$5.97M |
|
|
FRC
555
DELISTED
First Republic Bank
FRC
| $20.6M | 0.01% |
188,821
+48,724
| +35% | +$5.31M |
|
556
Labcorp
LH
$22.8B
| $20.4M | 0.01% |
126,025
+19,079
| +18% | +$3.09M |
|
|
MLPC
557
DELISTED
C-Tracks ETNs based on Performance of the Miller/Howard MLP Fundamental Index
MLPC
| $20.4M | 0.01% |
3,155,663
+34,000
| +1% | +$219K |
|
558
Oneok
OKE
$45.6B
| $20.3M | 0.01% |
781,461
+10,677
| +1% | +$277K |
|
559
HDFC Bank
HDB
$181B
| $20.2M | 0.01% |
405,260
+25,508
| +7% | +$1.27M |
|
560
Canadian National Railway
CNI
$57.8B
| $20.1M | 0.01% |
189,236
-73,810
| -28% | -$7.84M |
|
561
IQVIA
IQV
$31.9B
| $20.1M | 0.01% |
127,205
+17,211
| +16% | +$2.71M |
|
562
Vanguard Information Technology ETF
VGT
$102B
| $19.8M | 0.01% |
63,550
-4,641
| -7% | -$1.45M |
|
563
BioMarin Pharmaceuticals
BMRN
$10.5B
| $19.8M | 0.01% |
259,963
-5,204
| -2% | -$396K |
|
564
Quest Diagnostics
DGX
$20.2B
| $19.8M | 0.01% |
172,621
+31,724
| +23% | +$3.63M |
|
565
National Beverage
FIZZ
$3.64B
| $19.8M | 0.01% |
580,844
+95,524
| +20% | +$3.25M |
|
566
Trip.com Group
TCOM
$47.3B
| $19.7M | 0.01% |
633,257
-552,987
| -47% | -$17.2M |
|
567
Rollins
ROL
$27.4B
| $19.6M | 0.01% |
543,137
+178,334
| +49% | +$6.44M |
|
568
Toronto Dominion Bank
TD
$130B
| $19.5M | 0.01% |
423,097
-44,300
| -9% | -$2.04M |
|
569
Garmin
GRMN
$45.9B
| $19.4M | 0.01% |
204,640
+20,276
| +11% | +$1.92M |
|
570
F5
FFIV
$18.7B
| $19.3M | 0.01% |
156,918
+19,814
| +14% | +$2.43M |
|
571
Sumitomo Mitsui Financial
SMFG
$108B
| $19.2M | 0.01% |
3,439,117
+236,587
| +7% | +$1.32M |
|
572
Southwest Airlines
LUV
$16.1B
| $19.2M | 0.01% |
511,862
-10,156
| -2% | -$381K |
|
573
Infosys
INFY
$71.1B
| $19.2M | 0.01% |
1,389,781
+115,489
| +9% | +$1.59M |
|
574
Old Dominion Freight Line
ODFL
$30.5B
| $19.2M | 0.01% |
212,008
+40,646
| +24% | +$3.68M |
|
575
Novartis
NVS
$245B
| $19.1M | 0.01% |
220,064
+521
| +0.2% | +$45.3K |
|